Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Halozyme common stock, representing 0% of the class. The filing explains Vanguard underwent an internal realignment and certain subsidiaries will report disaggregated holdings in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is dated 03/13/2026 with a signature dated 03/27/2026. The filing states Vanguard's subsidiaries pursue the same investment strategies and that no single other person’s interest exceeds 5%.
HALOZYME THERAPEUTICS, INC. filed an initial ownership report for Interim CFO David A. Ramsay. This Form 3 shows his status as an officer but does not list any equity transactions or holdings in the provided data. It is an administrative disclosure of insider status rather than a trading event.
Halozyme Therapeutics, Inc. has issued its 2026 proxy for an online-only annual stockholder meeting on May 5, 2026. Stockholders will vote on electing two Class I directors, an advisory say-on-pay resolution for named executive officers, and ratifying Ernst & Young LLP as auditor for 2026.
The Board highlights a majority-vote standard for uncontested director elections, a fully independent board except for the CEO, and active board committees overseeing audit, compensation, and governance. Executive pay is heavily weighted to performance-based equity, with 2025 incentives tied to revenue and Adjusted EBITDA goals and strong stock performance, including record 2025 revenue of $1,397 million and 52% royalty revenue growth.
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while it continues an active search for a permanent CFO. Ramsay previously served as Halozyme’s CFO across multiple periods and has more than 30 years of financial leadership in biotechnology.
As Interim CFO he will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units that vest on June 30, 2026, subject to continued employment and a one-year holding period. If he remains Interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs that vest on his employment termination date, also with a one-year holding period.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported an exercise-and-sell transaction in company stock. On March 9–10, 2026, she exercised options to acquire a total of 21,546 shares of common stock at an exercise price of $33.51 per share.
Over the same two days, she conducted open-market sales totaling 28,857 shares of common stock at weighted average prices around $67.64–$68.25, with specific trades executed in price ranges disclosed in the footnotes. Following these transactions, she directly holds 7,055 shares of common stock and retains 67,678 options to purchase common stock.
HALO submitted a Form 144 notice reporting proposed sales of Common stock and disclosing a recent sale. The filing shows a reported sale by Cortney A. Caudill of 20,000 shares on 03/09/2026 for $1,356,062. The notice lists several issuances/vestings and an option exercise with quantities of 4,663, 1,546, and 2,648 shares tied to vesting or exercise dates in 2024–2026.
Morgan Stanley Smith Barney LLC reports a Rule 144 sale notice for 20,000 common shares. The filing states the shares relate to an exercise of options under a registered plan and lists the transaction date as 03/09/2026 on NASDAQ. The filing indicates cash as the consideration and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a combination of option exercises and share sales. Over March 2–4, 2026, she exercised options to acquire 50,000 shares of common stock at an exercise price of $12.07 per share.
She then sold 50,000 shares of common stock in multiple open‑market transactions under a pre‑established Rule 10b5‑1 trading plan, at weighted average prices within ranges between $68.22 and $71.36 per share. After these transactions, she directly owned 767,780 common shares.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported routine equity award activity. On February 20, 2026, 2,666 Restricted Stock Units vested and were settled into 2,666 shares of common stock, reflecting an exercise or conversion of derivative securities at a stated price of $0.0000 per share.
To cover tax withholding obligations from this vesting, 1,037 common shares were automatically withheld by the issuer at a price of $70.98 per share, as noted in the footnotes. After these transactions, Caudill directly owned 14,366 shares of common stock and 7,998 Restricted Stock Units. These movements reflect compensation-related settlements and tax withholding rather than open-market buying or selling.